Niva Bupa Health Insurance Share Price Analysis April 2026
Niva Bupa Health Insurance Company Limited (formerly Max Bupa) is one of India’s largest standalone health insurers (SAHI), incorporated in 2008 and licensed by IRDAI in February 2010. It is a subsidiary of Bupa Singapore Holdings Pte. Ltd., which brings international healthcare insurance expertise from a global organisation serving 50+ million customers. The company listed on NSE and BSE in November 2024, raising ₹2,200 crore through its IPO.
The company underwrites primarily health insurance — individual/family, senior citizens, critical illness, personal accident, corporate/group, and travel. It operates across 22 states and four union territories, with a network of 10,000+ cashless hospitals. As of 9M FY26, Niva Bupa covered approximately 17+ million lives, with retail health market share of 10.0% among SAHIs and 5.31% of overall health insurance GDPI.
Revenue Mix: The business is split between retail (~65% of mix by GWP) and group/corporate (~35%). The retail book carries higher loss ratios (~66%) vs. group (~58%), but retention economics are superior with renewal rates of 91.8% and a growing multi-year policy base. The 1/N accounting shift (proportional premium recognition for multi-year policies per IRDAI regulations) created accounting noise in FY25 GWP, but the underlying business grew ~32% on a like-to-like basis.
| Metric | FY22 | FY23 | FY24 | FY25 | 9M FY26 | Trend |
|---|---|---|---|---|---|---|
| GWP (₹ Cr) | 1,822 | 2,735 | 3,929 | ~5,500* | 6,309 | ▲ Strong |
| Net Earned Premium (₹ Cr) | 1,410 | 2,070 | 3,820 | 4,894 | — | ▲ +28% FY25 |
| PAT / (Loss) – iGAAP (₹ Cr) | (120) | (41) | 82 | 214 | 208 | ▲ Turnaround |
| PAT – IFRS (₹ Cr) | — | — | 106 | 203 | — | ▲ +91% FY25 |
| Combined Ratio (%) | ~115% | ~106% | 98.8% | 101.2%* | ~103% | ▬ 1/N impact |
| Loss Ratio (%) | ~72% | ~67% | 59.0% | 61.2% | ~62-64% | ▬ Slight ↑ |
| EOM (Expense of Mgmt) % | ~44% | ~40% | 39.3% | 37.4% | 35.0% | ▲ Improving |
| Claims Settlement Ratio | ~90% | 91.0% | 91.9% | 92.4% | — | ▲ Steady ↑ |
| AUM (₹ Cr) | — | — | — | ~7,000 | 8,927 | ▲ Growing |
| GWP CAGR (FY22–FY24) | 41.3% CAGR — One of the fastest-growing SAHIs in India | |||||
*FY25 GWP impacted by 1/N accounting change per IRDAI. Like-to-like growth was ~32%. Combined ratio adj. for 1/N = 96.1% (270 bps improvement over FY24). Q1 FY26 net loss of ₹91 Cr and Q2 FY26 net loss of ₹35 Cr reflect seasonality and medical inflation headwinds; Q3 FY26 net loss ₹87.6 Cr. Full-year profitability remains as 9M PAT is ₹208 Cr under IFRS.
The DCF assumes GWP CAGR of ~22% over FY26–FY28, moderating to ~15% in FY29–FY31 as penetration deepens. Normalised profit margins (iGAAP PAT margin on NEP) are assumed to reach 5–6% by FY28 as the EOM ratio converges to the 36% IRDAI cap and operating leverage kicks in. Investment yield on AUM is modeled at 7.2–7.5% — conservative relative to the company’s 7.3% realised yield on ₹8,927 Cr AUM. Key sensitivity: every 100 bps change in WACC moves intrinsic value by ~₹8–10/share. For insurance companies, Price-to-Embedded Value (P/EV) and Price-to-GWP multiples are often used alongside DCF.
| Year | GWP Est. (₹ Cr) | NEP Est. | PAT Est. (₹ Cr) | EOM (%) | Combined Ratio |
|---|---|---|---|---|---|
| FY26E | ~8,200 | ~6,500 | ~260 | 35.5% | ~101–102% |
| FY27E | ~10,200 | ~8,000 | ~380 | 34.5% | ~99–100% |
| FY28E | ~12,500 | ~9,800 | ~540 | 33.5% | ~97–98% |
Consensus analyst target: ₹86.20 (avg of 5 analysts; range ₹76–₹100). Current CMP of ₹73.80 offers ~17% upside to consensus. The stock is ~22% off its 52-week high of ₹95.21 and ~8% above its 52-week low of ₹68.54.
GWP growth fails to sustain 20%+. Loss ratio creep above 65% for 2+ consecutive quarters. EOM misses IRDAI compliance trajectory. Profit growth disappoints vs. consensus FY27 estimates.
Regulatory headwinds materialise (IRDAI tightens pricing guidelines). Market share plateaus as Star Health and Care Health aggressively price down. Promoter/Bupa stake sale rumours emerge post lock-in.
Catastrophic claims event (pandemic, systemic fraud). Solvency ratio breach below 1.5×. IRDAI licensing risk. Persistent underwriting losses leading to capital raise dilution risk.
Operating Leverage: As the renewal book scales, trail commissions (~18–19% of renewal GWP) replace the higher upfront commissions on new business. This, combined with technology investments reducing per-policy operating costs, should compress EOM toward the 36% IRDAI cap and eventually well below it.
GST Catalyst: The government is actively considering GST exemption on retail life and health insurance premiums. If implemented, it would significantly reduce effective premium costs for consumers, acting as a demand multiplier. This alone could add 2–3 percentage points to industry GWP CAGR.
AI & Digital: Niva Bupa has materially invested in AI-driven claims processing, fraud detection, and customer onboarding. The company has been recognised as a Great Place to Work for six consecutive years. Digital-first policy issuance reduces intermediary costs and improves retention.
New Product: ‘Rise’: Launched in 2025 with Flexi-pay, Return, Smart Cash & Unlimited Digital Consultations — targeting underserved middle-income segment with higher retention potential.
| Company | Type | Mkt Cap (Cr) | GWP Growth | Loss Ratio | Combined Ratio | P/GWP | ROE |
|---|---|---|---|---|---|---|---|
| Niva Bupa (NIVABUPA) | SAHI | ~13,000 | ~26% (9M FY26) | 61–63% | ~101%* | ~1.6× | 6.4% (3Y) |
| Star Health Insurance | SAHI | ~35,000 | ~15% FY25 | ~65–67% | ~100–102% | ~2.2× | ~12% |
| Care Health Insurance | SAHI | Unlisted | ~25% | ~60% | ~98% | N/A | N/A |
| Aditya Birla Health Ins. | SAHI | Unlisted | ~30% | ~62% | ~103% | N/A | N/A |
| ICICI Lombard (General) | Multi-line | ~85,000 | ~15% | ~70% | ~104% | ~4.5× | ~18% |
*FY25 combined ratio at 96.1% on like-to-like basis ex-1/N impact. SAHI = Standalone Health Insurer. Peer data approximate based on available public filings.
